Eisai Global Executive and Leadership Team

Haruo Naito, the Director, Representative Corporate Officer and Chief Executive Officer at Eisai Global, directs the overarching corporate strategy and operational execution. Naito guides the company's commitment to a human health care approach, ensuring that pharmaceutical development and services extend beyond traditional boundaries to address patient needs comprehensively. This leadership role involves setting the vision for research and development, particularly in patient-centered healthcare solutions across North America, Europe, Asia Pacific, and the Middle East. By fostering innovation and maintaining a strong focus on market impact, Haruo Naito drives Eisai Global's mission to improve patient outcomes and enhance global health.

Rodney Dausch, the Chief Financial Officer at Eisai Global, manages all financial operations and strategic fiscal planning. Dausch oversees budgeting, forecasting, and financial reporting, ensuring fiscal health and supporting the company's global expansion initiatives across key regions like the United States, Japan, China, and the United Kingdom. This role is critical in allocating resources for research and development, particularly for patient-centered healthcare solutions. By optimizing financial performance and managing investment strategies, Rodney Dausch directly contributes to Eisai Global's business-to-business and business-to-consumer operations, reinforcing the company's market position and long-term sustainability.

Toshimitsu Uenaka, the President, Epochal Precision Anti-Cancer Therapeutics (Epat) at Eisai Global, spearheads the development and strategic direction of innovative oncology treatments. Uenaka focuses on precision medicine and cutting-edge research to create novel anti-cancer therapeutics, aligning with Eisai's commitment to patient-centered healthcare solutions. This leadership role involves driving research and development initiatives within the pharmaceutical sector, particularly for complex diseases. By advancing the Epat division's pipeline and ensuring rigorous scientific validation, Toshimitsu Uenaka significantly contributes to Eisai Global's mission of improving patient lives through advanced pharmaceutical development.

Susumu Ebihara, the President, Quality Cfu at Eisai Global, directs all quality assurance and control functions across the company's pharmaceutical manufacturing operations. Ebihara ensures adherence to the highest industry standards and regulatory requirements, maintaining product integrity and patient safety across global markets. This critical role supports Eisai's human health care approach by guaranteeing the reliability and efficacy of all medicines developed and produced. By implementing stringent quality management systems and fostering a culture of excellence, Susumu Ebihara upholds Eisai Global's reputation for producing high-quality pharmaceuticals and delivering trusted healthcare solutions.

Cynthia Schwalm, the President at Eisai Global, oversees significant operational and strategic initiatives, particularly within key regional markets such as North America. Schwalm drives the implementation of Eisai's human health care approach, ensuring that pharmaceutical services and product development align with patient needs and market demands. This leadership position involves managing cross-functional teams and fostering collaboration to advance research and development efforts. By focusing on market penetration and operational excellence, Cynthia Schwalm contributes to Eisai Global's business-to-business and business-to-consumer operations, strengthening its presence and impact in the pharmaceutical sector.

Hiroyuki Murayama, the President (Japan) & Promotion Department Manager, Product Strategy at Eisai Global, leads the company's strategic product planning and promotional activities within the crucial Japanese market. Murayama ensures that Eisai's pharmaceutical offerings effectively meet the specific healthcare needs of patients in Japan, aligning with the broader human health care philosophy. This dual role involves driving product strategy development and managing promotional campaigns to maximize market reach and patient access. By expertly navigating the Japanese pharmaceutical landscape, Hiroyuki Murayama enhances Eisai Global's commitment to patient-centered healthcare solutions and strengthens its regional business operations.

Kazuhiko Tamura, the Vice President and President, Eisai Demand Chain Systems at Eisai Global, directs the optimization and management of the company's supply chain and distribution networks. Tamura ensures efficient product flow from manufacturing to patients across all operating regions, including North America, Europe, and Asia Pacific. This role is fundamental to Eisai's business-to-business and business-to-consumer operations, guaranteeing timely access to medicines. By implementing advanced demand chain strategies and fostering operational resilience, Kazuhiko Tamura supports Eisai Global's commitment to delivering patient-centered healthcare solutions and maintaining a robust global presence.

Makoto Hoketsu, the Vice President & Chief Information Officer at Eisai Global, architects and oversees the company's entire information technology infrastructure and digital strategy. Hoketsu ensures robust data management, cybersecurity, and the seamless integration of technology across all business functions, supporting Eisai's global operations in North America, Europe, Asia Pacific, and the Middle East. This leadership position is vital for enhancing research and development capabilities and enabling patient-centered healthcare solutions through advanced digital platforms. By driving technological innovation and ensuring operational efficiency, Makoto Hoketsu supports Eisai Global's comprehensive approach to healthcare delivery and pharmaceutical development.